First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1315-1324

  Moschetti, Viktoria ^a   Boland, Katja ^a   Feifel, Ulrich ^a   Hoch, Anja ^a   Zimdahl Gelling, Heike ^a   Sand, Michael ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Alzheimer's disease; cognitive impairment; PDE9A; phosphodiesterase inhibitor; schizophrenia

Indexed keywords

BI 409306; CYTOCHROME P450 2C19; PHOSPHODIESTERASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; COLOR VISION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXTRASYSTOLE; EYE DISEASE; FIRST IN HUMAN STUDY; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PARESTHESIA; PAROSMIA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PHOTOPSIA; PLASMA CONCENTRATION-TIME CURVE; PRESYNCOPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SOMNOLENCE; TABLET FORMULATION; XEROSTOMIA;

EID: 85027946593     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13060     Document Type: Article

References (19)

1. Hu NW, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol Biochem Behav 2012; 100: 855–62.
2. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 2012; 100: 665–77.
3. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31–9.
4. Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain 2006; 129: 1659–73.
5. Reymann KG, Frey JU. The late maintenance of hippocampal LTP: requirements, phases, ‘synaptic tagging’, ‘late-associativity’ and implications. Neuropharmacology 2007; 52: 24–40.
6. Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, et al. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 2003; 467: 566–80.
7. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010; 59: 367–74.
8. Dorner-Ciossek C, Giovannini R, Rosenbrock H. BI 409306, a novel phosphodiesterase 9A inhibitor, part I: potency, selectivity and in-vitro functional characterization on synaptic plasticity. International Congress on Schizophrenia Research: Schizophrenia Bull 2015; 41: S31.
9. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011; 61: 665–76.
10. Kroker KS, Mathis C, Marti A, Cassel JC, Rosenbrock H, Dorner-Ciossek C. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging 2014; 35: 2072–8.
11. Kroker KS, Rast G, Giovannini R, Marti A, Dorner-Ciossek C, Rosenbrock H. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012; 62: 1964–74.
12. Rosenbrock H, Marti A, Koros E, Runge F, Fuchs H, Giovannini R, et al. BI 409306, a novel phosphodiesterase 9A inhibitor, part II: in-vivo characterization regarding target engagement and cognition tasks in rodents. Abstracts for the 15th International Congress on Schizophrenia Research. Schizophrenia Bull 2015; 41 (Suppl. 1): S36.
13. Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther 2012; 341: 396–409.
14. van der Staay FJ, Rutten K, Barfacker L, Devry J, Erb C, Heckroth H, et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008; 55: 908–18.
15. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47: 211–8.
16. Dhingra A, Tummala SR, Lyubarsky A, Vardi N. PDE9A is expressed in the inner retina and contributes to the normal shape of the photopic ERG waveform. Front Mol Neurosci 2014; 7: 60.
17. Evans RM, Nicholas T, Le V, Qiu R, Martin W, Martin D, et al. Safety and pharmacokinetics of PF-04447943, a PDEA inhibitor, in single and multiple dose phase 1 studies in healthy volunteers. Alzheimers Dement 2010; 6: S135.
18. Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res 2014; 11: 413–21.
19. Boland K, Moschetti V, Dansirikul C, Pichereau S, Gheyle L, Sand M. Randomized, double-blind, placebo-controlled, parallel-group proof of mechanism study to assess the pharmacokinetics and pharmacodynamic effect of different single oral doses of BI 409306 in healthy male volunteers. Abstracts for the 15th International Congress on Schizophrenia Research. Schizophrenia Bull 2015; 41 (Suppl. 1): S303.